Brought to you by 
Astellas and Drais, through new virtual firm Tacurion, develop ASP7035
08 May 2013
Executive Summary
Once again, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. (clinical-stage drug development) have signed an agreement for the development and commercialization of an Astellas compound, this time the Phase IIa-ready vasopressin V2 receptor selective agonist ASP7035 for nocturia (waking up at night to urinate). Astellas will transfer ownership of the compound to Tacurion Pharma Inc., a virtual company to be operated by Drais’ executive team.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas and Drais, through new virtual firm Tacurion, develop ASP7035
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice